Here are 4 top stocks in the growing medical marijuana industry that have a tremendous amount of potential for investors.
Tag Archives: Kalytera Therapeutics
MANHATTAN BEACH, Calif., June 2, 2016 /Weed Wire/ —Kalytera Therapeutics, Inc., (“Kalytera”) a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has entered into a technology licensing agreement (the “Agreement”) with Delivra Corp. (TSXV: DVA) (“Delivra”).
Marijuana Investor News decided to talk to the industry to see what its leaders really hope Santa leaves under the proverbial “tree,” or sets out with the stockings.
As the Western Hemisphere heads into fall, a strange thing is starting to happen across the pond. Not one but several companies who manufacture and distribute cannabinoid-processed end products are looking to European expansion.